

Choose a treatment that's right for your prostate cancer


Why Did My Doctor Order This Test?

When it comes to treatment decisions for intermediate or high-risk prostate cancer, one size does not fit all.

The Oncotype DX Genomic Prostate Score® (GPS™) test:

- is a genomic test
- can help your doctor determine how aggressive your treatment needs to be
- provides important information about likely outcomes of your cancer

With so many things to consider, side effects, quality of life, and more, this test can help you find the treatment plan that fits your life.




Jeff L.
Clinical researcher and dedicated grandfather of two. Navigating prostate cancer since 2017.

Genomic Testing – The Key to Knowing Your Cancer

Unlike a genetic test which assesses your hereditary risk for cancer, a genomic test analyzes cancer tissue to provide information on how a tumor might behave. It identifies changes in DNA that may be driving the growth of your tumor. By providing vital information such as how likely your cancer is to spread, genomic testing can help you and your doctor select an appropriate treatment course.†

How Does it Work?

	<p>1. The tissue from your original biopsy is sent to our lab for analysis. No additional procedures are required.</p>
	<p>2. Test results are sent to your doctor.</p>
	<p>3. You and your doctor review the results together.</p>




The Oncotype DX® GPS™ report will help your doctor determine how aggressive your treatment needs to be based on your tumor's characteristics.

†Loeb, Ross. *Curr Opin Urol*. 2017.

What Can I Expect from My Test Results?

Your results are reported as a Genomic Prostate Score (GPS™) on a scale of 0-100. A high GPS result indicates that more aggressive treatment may be needed. By reviewing the results with your doctor you'll get information that can help answer your important prostate cancer questions, such as those below.



How aggressive should my treatment plan be?
There are many different treatment options for prostate cancer - each with its own set of risks and side effects. Your GPS result can help you and your doctor determine an appropriate course of treatment.

Is my cancer going to come back?
Your GPS result can help you understand whether your cancer is likely to recur, spread from the original to other organs or lymph nodes (metastasis), or result in prostate cancer-specific death.


Over 1.5 million prostate, colon, and breast cancer patients have used an Oncotype DX® test to help guide their treatment decisions.*

The GPS test provides a personalized assessment of your cancer, helping you and your doctor discuss next steps with confidence.** Talk to your doctor today about how the Oncotype DX® GPS™ test can help guide your treatment decisions.

*Data on file
**Badani et al. Urol Pract 2015

Be Involved with Your Test Results

Schedule your follow-up appointment to discuss your GPS™ test result so you and your doctor can determine the appropriate treatment options.



“Without a genomic test, I might have chosen a less aggressive treatment plan and my disease would likely have gotten worse. Fortunately, my urologist and I selected a more appropriate plan based on my GPS result.”

*Jeff L.,
Prostate Cancer Patient*

Learn More About Your Insurance Options

84% of Oncotype DX® GPS™ assay patients have \$0 financial responsibility.***

To learn about Medicare coverage, private insurance coverage and financial assistance, contact our Customer Service group by phone at:

888-ONCOTYPE (888-622-6897)

or by email at:

customerservice@genomichealth.com.



Scan the QR code or visit **oncotypeiq.com/gps-results** for more information.

EXACT SCIENCES

*** This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid and commercial insurance. Patient cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurance provider can confirm if and how the Oncotype DX GPS assay will be covered. The number cited is based on historical patient billing data from 1/02/2020 to 12/31/2020. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about Oncotype DX Genomic Prostate Score assay coverage.

Oncotype, Oncotype DX, Oncotype DX Genomic Prostate Score, and GPS are trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. ©2021 Exact Sciences Corporation. All rights reserved. EXS40602_0821

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX Genomic Prostate Score® (GPS™) test may be right for you. The actual patients shown here used the Oncotype DX Genomic Prostate Score® (GPS™) test in making their treatment decisions with their physicians. Individual results may vary.